The cure rate of early stage non-Hodgkin’s lymphoma is between 20% and 75%, which should be determined according to the specific condition of the patient. Non-Hodgkin’s lymphoma is a malignant tumor of the blood system, and clinically it is classified into low-risk, low-intermediate-risk, intermediate-high-risk and high-risk types according to the pathological types, and its cure rate and prognosis are different, which are mainly determined by its pathological types. For low-risk early-stage non-Hodgkin’s lymphoma patients, the cure rate can reach about 75%; low-intermediate-risk patients have a cure rate of only about 50%, high-intermediate-risk patients have a cure rate of 40%, and high-risk patients have a cure rate of only about 20%, but there are variations in different patients’ physical conditions and treatment effects, and therefore the cure rate is not completely fixed. Cure rates vary for different pathologic subtypes, such as inert lymphoma, which is inherently incurable; diffuse large B-cell lymphoma, which can have a cure rate of more than 50% if treatment is standard; and T-cell lymphoma, which has a cure rate of less than 30%. In addition, according to the clinicopathologic stage of non-Hodgkin’s lymphoma, its survival rate will also be significantly improved if it is early stage, and its survival rate will be significantly decreased if it is advanced stage. Therefore, aggressive early treatment of non-Hodgkin’s lymphoma patients can improve the 5-year survival rate and also increase the cure rate. Treatment is based on chemotherapy, supplemented by other treatment modalities. The cure rate for non-Hodgkin’s lymphoma is relatively low, and it is important for patients to follow up closely and seek aggressive medical care.